Economic Evidence at the Local Level: Options for Making it More Useful

Kees van Gool, Gisselle Gallego, Marion Haas, Rosalie Viney, Jane Patricia Hall and Robyn Ward
Additional contact information
Kees van Gool: Centre for Health Economics Research and Evaluation (CHERE), University of Technology, Sydney, New South Wales, Australia
Robyn Ward: School of Medicine, University of New South Wales, Sydney, New South Wales, Australia

PharmacoEconomics, 2007, vol. 25, issue 12, pages 1055-1062

Abstract: Like other countries, Australia has had some success in incorporating economic evidence into national healthcare decisions. However, it has been recognised that this coverage does not extend to the local hospital or health region level. An extensive body of research has identified barriers to the use of economic evidence at the local level, leading some commentators to suggest that economic evaluation should only be targeted at national decision-making bodies. Yet, local decision makers in Australia and elsewhere make important choices about the uptake and diffusion of healthcare technologies. We propose a number of interrelated options to address the barriers that currently prohibit the use of economic evaluation by local decision makers in many jurisdictions. These include wider dissemination of user friendly models, inclusion of assessments of the cost impact of interventions on various budgets, and the establishment of an authoritative body that ensures the production of high quality economic models. It is argued that these options can have a significant impact on the way economic evaluations are conducted, reported, disseminated and used.

Keywords: Cost-effectiveness; Decision-making (search for similar items in EconPapers)
JEL-codes: C D I Z I1 I19 I18 I11 (search for similar items in EconPapers)
Date: 2007

Downloads: (external link)
http://pharmacoeconomics.adisonline.com/pt/re/phe/ ... -200725120-00006.pdf (application/pdf)
http://pharmacoeconomics.adisonline.com/pt/re/phe/ ... -200725120-00006.htm (text/html)
Pay per view

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: http://EconPapers.repec.org/RePEc:wkh:phecon:v:25:y:2007:i:12:p:1055-1062

Access Statistics for this article

PharmacoEconomics is edited by Christopher I. Carswell, MSc, MRPharmS

More articles in PharmacoEconomics from Wolters Kluwer Health | Adis
Series data maintained by Remco Bouckaert ().